Europe’s medicines watchdog on Friday rejected a marketing request for a new Alzheimer’s disease treatment, saying the risks of the medicine’s side effects, including potential brain bleeding, outweighed the benefits.
Europe’s medicines watchdog on Friday rejected a marketing request for a new Alzheimer’s disease treatment, saying the risks of the medicine’s side effects, including potential brain bleeding, outweighed the benefits.